Meeder Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-20
| Closed | -$2.64K | – | 1024 |
|
|
2025
Q1 | $2.64K | Sell |
20
-33
| -62% | -$4.11K | ﹤0.01% | 849 |
|
|
2024
Q4 | $4.43K | Buy |
+53
| New | +$4.36K | ﹤0.01% | 846 |
|
|
2024
Q3 | – | Sell |
-47
| Closed | -$3.22K | – | 979 |
|
|
2024
Q2 | $3.22K | Sell |
47
-37
| -44% | -$2.57K | ﹤0.01% | 819 |
|
|
2024
Q1 | $5.81K | Buy |
+84
| New | +$5.77K | ﹤0.01% | 620 |
|
|
2022
Q3 | – | Sell |
-367
| Closed | -$21K | – | 2411 |
|
|
2022
Q2 | $21K | Buy |
+367
| New | +$20.8K | ﹤0.01% | 1137 |
|
|
2021
Q3 | – | Sell |
-1,700
| Closed | -$69K | – | 2670 |
|
|
2021
Q2 | $69K | Buy |
+1,700
| New | +$62.8K | ﹤0.01% | 1025 |
|
|
2020
Q4 | – | Sell |
-1,582
| Closed | -$41K | – | 2273 |
|
|
2020
Q3 | $41K | Buy |
+1,582
| New | +$36.1K | ﹤0.01% | 994 |
|
|
2020
Q2 | – | Sell |
-423
| Closed | -$7K | – | 2537 |
|
|
2020
Q1 | $7K | Sell |
423
-313
| -43% | -$6.8K | ﹤0.01% | 1676 |
|
|
2019
Q4 | $26K | Sell |
736
-409
| -36% | -$4.91K | ﹤0.01% | 1271 |
|
|
2019
Q3 | $9K | Sell |
1,145
-733
| -39% | -$7.03K | ﹤0.01% | 1582 |
|
|
2019
Q2 | $24K | Buy |
1,878
+1,566
| +502% | +$20.1K | ﹤0.01% | 1177 |
|
|
2019
Q1 | $4K | Sell |
312
-427
| -58% | -$5.46K | ﹤0.01% | 1459 |
|
|
2018
Q4 | $8K | Buy |
+739
| New | +$11.9K | ﹤0.01% | 1311 |
|
|
2017
Q3 | – | Sell |
-149
| Closed | -$2K | – | 1789 |
|
|
2017
Q2 | $2K | Sell |
149
-599
| -80% | -$6.95K | ﹤0.01% | 1438 |
|
|
2017
Q1 | $12K | Sell |
748
-1,268
| -63% | -$18.4K | ﹤0.01% | 821 |
|
|
2016
Q4 | $30K | Buy |
+2,016
| New | +$28.5K | ﹤0.01% | 610 |
|
|
2016
Q2 | – | Sell |
-3,574
| Closed | -$99K | – | 972 |
|
|
2016
Q1 | $99K | Buy |
+3,574
| New | +$119K | 0.01% | 698 |
|
Other funds holding ITCI
Meeder Asset Management's ITCI Position: Q2 2025 in Review
Meeder Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 20 shares — an estimated $2.64K sold.
Meeder Asset Management first reported a position in ITCI in Q1 2016 and held it in 17 quarters. The position peaked at $99K in Q1 2016. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Meeder Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Meeder Asset Management sold 20 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $2.64K.
- Meeder Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 17 quarters.
- Meeder Asset Management's Intra-Cellular Therapies Inc. position peaked at $99K in Q1 2016.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Meeder Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.